Mesenkia Therapeutics AB
559443-7021ActiveDeveloping novel antibodies to treat aggressive brain cancer glioblastoma.
Pre-clinical Biotechnology Companymesenkiatherapeutics.com
Overview
- 1–4
- Employees
- 200–299K SEK
- Revenue
- 2023
- Founded
Description
Mesenkia is a pre-clinical biotechnology company focused on developing breakthrough therapies for glioblastoma, an aggressive form of brain cancer. The company specializes in creating next-generation biological drug candidates, specifically single domain antibodies. Their scientific foundation stems...
Tags
B2BHealthTechPharmaceuticals
Keywords
BiotechDrug Development